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S214 Poster Session Iensuing 3 mo. By contrast, CAR.19z cells were barely detectable af-
ter infusion, showed no expansion and disappeared rapidly. Follow-
ing treatment, 2 patients had stable disease for up to 6 mo and 4 had
progressive disease.
In conclusion, infusion of both CAR.19z and CD19-28zT cells is
safe at the doses used. Direct comparison of each cell product in
individual patients showed that the CD28 endodomain enhances
expansion and persistence of the CAR T cells. The limited clinical
benefits suggest that additional modifications will be required and
our approach will allow these changes to be systematically evaluated
even in small-scale clinical studies.164
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There is increasing evidence for the role of BK virus in the aetiol-
ogy of haemorrhagic cystitis and renal impairment post haemo-
poietic stem cell transplant (HSCT). Cellular therapy for immune
reconstitution post HSCT has been used clinically for CMV, EBV
and adenovirus. Broadening the scope of viral targets in this type
of therapy is desirable to reduce the burden of opportunistic infec-
tions in this patient group.
Methods: Monocyte derived dendritic cells or peripheral blood
mononuclear cells were pulsed with mixes of overlapping peptides
covering the 5 BKV proteins (VP1, VP2, VP3, LTA and STA).
These were used to stimulate T cells on days 1 and 7 and cells
were cultured for 21 days with increasing doses of IL-2 from day
7. The cellular product was then analysed for phenotype, BKV spec-
ificity and functionality by examining cytokine production and
cytotoxicity.
Results: Cellular proliferation was seen in all donors, mean fold in-
crease in total viable cells was 5.9 fold. All cell products were mainly
CD3 cells (mean 94.1%) with individual variation in CD4:CD8 ratio
(ranges: CD4 9.7 to 97.5%; CD8 0.9 to 77%). T cell subsets analysis
showed the majority of cells to be Tem (mean 71.2%), with a sizable
minority of Tcm (mean 21.5%). Data on antigen specificity was
available in 11 of 15 cultures. Within cultures, BKV responsive cells
varied (CD3 mean 12.7%, CD8 mean 15.2%, CD4 mean 12.5%,).
There was heterogeneity in the specificity of cells to different BKV
proteins. Most responses were directed to VP1, LTA and STA
with smaller magnitude responses seen to VP2 and VP3. The quality
of the cytokine response was assessed bymultiparameter flow cytom-
etry for IFN-g, TNF and IL-2. In all cases, the percentage of cells
producing multiple cytokines to stimulation with BKV proteins
was high (for CD3 mean triple cytokine 37.5%, double 34.3% and
single 28.2%). Cytotoxicity was assessed using CD107a/b expression
and the CARE-LASS cell lysis assay. CD107 expression was present
in both CD8 and CD4. This was higher in CD8 cells and lysis of
antigen coated target cells correlatedwith the presence of CD107 ex-
pression on CD8 cells.
Discussion:The clinical utility of this product will be determined in
clinical trials of adoptive immunotherapy following HSCT or renal
transplantation. This method for large-scale expansion of BKV spe-
cific CTL could also be utilised for analysis of BKV targeted immune
responses and epitope identification.165
EXPANDED HUMAN INKT CELLS EXHIBIT TH2 POLARIZATION AND
DIRECT CYTOTOXICITY AGAINST HEMATOLYMPHOID TUMOR TARGETS
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Memphis, TNCD1d-restricted invariant NKT (iNKT) cells are rare but potent
innate regulatory cells capable of immune modulation after trans-
plantation via robust production ofTh1/Th2 cytokines, as well as tu-
mor immunosurveillance via direct cytotoxicity. Protocols to expand
iNKT cells and tailor their cytokine secretion would broaden
their application in transplant immunotherapy. We have optimized
a protocol for ex vivo expansion of highly purified human
CD31Va241 iNKT cells from a variety of cell sources including hu-
man peripheral blood (PB), bone marrow, and umbilical cord blood.
PB CD31Va241 iNKT cells (. 98% pure by sort) were expanded
using PB-derived autologous APCs, Va24-specific TCR stimulation
without added glycolipids, and low-dose IL-2 and IL-7. This results
inmean. 103-fold expansion, with peak yields at day 14-21 (range, 3
 106 - 7  107 iNKT cells from 103 - 104 starting CD31Va241
cells). Expanded iNKT cells are CD31CD4negVa241 and retain
viability in culture through day 49. At 21 days, these iNKT cells se-
crete high IL-10 and IL-5, moderate IL-4 and IFN-g, and low IL-2
and IL-13 in anti-CD2/CD3/CD28 bead-stimulated Luminex
supernatant assay. Day 21 expanded iNKT cells maintained an IL-
4hiIFN-glo phenotype even with potent Th1-polarizing stimuli
[100 ng/mL of the glycolipid ligand alpha-galactosyl ceramide (a-
GalCer)], and are dose-dependent suppressors of sorted autologous
CD31CD4negVa24neg (. 95% CD31CD81) responders in 72-hr
CFSE MLR. Non-glycolipid activation of day 21 iNKT cells in-
duced high levels of cytolytic effectormolecules, including granzyme
B. We measured cytotoxicity of activated day 21 iNKT cells follow-
ing co-incubation of iNKT cells versus control effector populations
with firefly luciferase-transduced RS4,11 andNalm6 (B-ALL),U937
(monocytic) and K562 (CML) targets. iNKT cell effectors (E) dem-
onstrated dose-dependent cytotoxicity against B-ALL targets (T)
(e.g. Nalm6: 31.2 69.1% at E:T 0.1:1, 32.6 64.4% at E:T 0.5:1,
48.565.7% at E:T 1:1), with no significant cytotoxicity against my-
eloid targets (e.g. K562: 12.3 61.6% at E:T 0.1:1, 14.9 63.0% at
E:T 0.5:1, 14.2 62.6% at E:T 1:1). Our results indicate that human
iNKT cells expressing high levels of Th2 and regulatory cytokines
can be potently expanded ex vivo without exogenous glycolipid stim-
ulation and exert significant cytotoxicity against B-ALL targets. This
supports their potential for application in anti-tumor or regulatory
immunotherapy in the pre- and post-transplant setting.166
ADOPTIVE TRANSFER THERAPY USING EXPANDED MELANOMA-
SPECIFIC T CELLS PROGRAMMED EX VIVO FOR IMPROVED EFFICACY
IN VIVO
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Adoptive cell transfer (ACT) of autologous tumor-infiltrating
lymphocytes (TIL) mediates tumor regression in 50% of Stage
IV melanoma patients previously refractory to all other types of
therapy. Further improvement of this therapy based on current
technology (using OKT3 and allogeneic PBMC) to propagate T
cells has reached a point of diminishing returns due to the techni-
cally cumbersome and resource-intensive production of TIL for
clinical administration. The extended culture times needed to gen-
erate sufficient numbers of TIL typically results in acquisition of
terminally-differentiated T cells with loss of effector memory
(EM) function and reduced antigen specificity, resulting in poor
in vivo persistence and reduced therapeutic potential. Compound-
ing this problem is that TIL cannot be expanded from many mel-
anoma patients, leaving them without an option for cellular
therapy. To improve ACT, here we show that K562 cells can func-
tion as artificial antigen-presenting cells (aAPC) for propagating
melanoma-specific T cells from both TIL and peripheral blood.
K562 were genetically modified to function as ‘‘generic’’ aAPC
for in vitro propagation of T cells with central/effector memory
phenotypes by enforced expression of the costimulatory molecules
CD86 and 41BB-L in addition to membrane-bound versions of the
cytokines IL7/IL15/IL21. As K562 do not express endogenous
HLA A and B molecules engendering allogeneic responses, they
were genetically modified as ‘‘specialized’’ aAPC using the Sleeping
